Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-PREDICT
NCT06806930Phase 2Recruiting
- Sponsor
- George Washington University
- Start
- Oct 2024
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in breast cancer (3 cohorts), sponsored by George Washington University. Primary endpoint: Response to neoadjuvant endocrine therapy at 52 weeks. Started Oct 2024; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06806930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806930.